Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 4
2015 12
2016 14
2017 21
2018 17
2019 18
2020 18
2021 29
2022 15
2023 15
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

142 results

Results by year

Filters applied: . Clear all
Page 1
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
Soria JC, Tan DSW, Chiari R, Wu YL, Paz-Ares L, Wolf J, Geater SL, Orlov S, Cortinovis D, Yu CJ, Hochmair M, Cortot AB, Tsai CM, Moro-Sibilot D, Campelo RG, McCulloch T, Sen P, Dugan M, Pantano S, Branle F, Massacesi C, de Castro G Jr. Soria JC, et al. Lancet. 2017 Mar 4;389(10072):917-929. doi: 10.1016/S0140-6736(17)30123-X. Epub 2017 Jan 24. Lancet. 2017. PMID: 28126333 Clinical Trial.
BACKGROUND: The efficacy of ceritinib in patients with untreated anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC) is not known. ...The most common adverse events were diarrhoea (in 160 [85%] of 189 patients), nausea (130 [69%]), vomitin …
BACKGROUND: The efficacy of ceritinib in patients with untreated anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung canc …
From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC.
Ou SI, Lee ATM, Nagasaka M. Ou SI, et al. Crit Rev Oncol Hematol. 2023 Jul;187:104019. doi: 10.1016/j.critrevonc.2023.104019. Epub 2023 May 13. Crit Rev Oncol Hematol. 2023. PMID: 37187318 Free article. Review.
Six ALK TKIs (crizotinib, ceritinib, alectinib, brigatinib, lorlatinib, ensartinib) have received first-line treatment indication of advanced ALK+ NSCLC in various countries. ...Median PFS was 33.3 months among lorlatinib-treated EML4-ALK v3 patients. CNS AE occurre …
Six ALK TKIs (crizotinib, ceritinib, alectinib, brigatinib, lorlatinib, ensartinib) have received first-line treatment indication of …
Targeted therapy for advanced anaplastic lymphoma kinase (<I>ALK</I>)-rearranged non-small cell lung cancer.
Cameron LB, Hitchen N, Chandran E, Morris T, Manser R, Solomon BJ, Jordan V. Cameron LB, et al. Cochrane Database Syst Rev. 2022 Jan 7;1(1):CD013453. doi: 10.1002/14651858.CD013453.pub2. Cochrane Database Syst Rev. 2022. PMID: 34994987 Free PMC article. Review.
We assessed the certainty of evidence using GRADE. Primary outcomes were progression-free survival (PFS) and adverse events (AE); secondary outcomes were overall survival (OS), OS at one year, overall response rate (ORR) by RECIST (Response Evaluation Criteria in So …
We assessed the certainty of evidence using GRADE. Primary outcomes were progression-free survival (PFS) and adverse events (AE …
Ceritinib for the treatment of non-small cell lung cancer.
Landi L, Cappuzzo F. Landi L, et al. Drugs Today (Barc). 2014 Jul;50(7):465-73. doi: 10.1358/dot.2014.50.7.2133568. Drugs Today (Barc). 2014. PMID: 25101329 Review.
Overcoming resistance is the major challenge in clinical oncology and many molecules are currently under evaluation, including ceritinib (LDK-378). Ceritinib is an oral, potent, second-generation ALK inhibitor recently approved by the U.S. ...Preclinical data showed …
Overcoming resistance is the major challenge in clinical oncology and many molecules are currently under evaluation, including ceritinib …
The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.
Mok TSK, Crino L, Felip E, Salgia R, De Pas T, Tan DSW, Chow LQM. Mok TSK, et al. Cancer Treat Rev. 2017 Apr;55:181-189. doi: 10.1016/j.ctrv.2017.03.006. Epub 2017 Mar 30. Cancer Treat Rev. 2017. PMID: 28427013 Free article. Review.
There is now a next generation of ALK inhibitors, including two that have been approved-ceritinib and alectinib-and others that are in development-brigatinib, lorlatinib and X-396. Ceritinib and the other next-generation ALK inhibitors are more potent than crizotini …
There is now a next generation of ALK inhibitors, including two that have been approved-ceritinib and alectinib-and others that are i …
Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS).
Omar NE, Fahmy Soliman AI, Eshra M, Saeed T, Hamad A, Abou-Ali A. Omar NE, et al. ESMO Open. 2021 Dec;6(6):100315. doi: 10.1016/j.esmoop.2021.100315. Epub 2021 Dec 2. ESMO Open. 2021. PMID: 34864500 Free PMC article.
Further, we searched for adverse events on the preferred term (PT) level based on case reports in the literature. ...For adverse events on the PT level, we found several significant signals, including pneumothorax with crizotinib (PRR 3.29, ROR 3.29), ceritinib …
Further, we searched for adverse events on the preferred term (PT) level based on case reports in the literature. ...For adverse …
Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: A systematic review and network meta-analysis.
Peng Y, Zhao Q, Liao Z, Ma Y, Ma D. Peng Y, et al. Cancer. 2023 Apr 15;129(8):1261-1275. doi: 10.1002/cncr.34664. Epub 2023 Feb 7. Cancer. 2023. PMID: 36748799 Free article.
RESULTS: The authors included a total of nine studies including 2441 patients and seven first-line treatments (ensartinib, brigatinib, crizotinib, lorlatinib, alectinib, ceritinib, and pemetrexed-based chemotherapy). Overall, lorlatinib appeared to confer the best progress …
RESULTS: The authors included a total of nine studies including 2441 patients and seven first-line treatments (ensartinib, brigatinib, crizo …
Ceritinib (LDK378): a potent alternative to crizotinib for ALK-rearranged non-small-cell lung cancer.
Li S, Qi X, Huang Y, Liu D, Zhou F, Zhou C. Li S, et al. Clin Lung Cancer. 2015 Mar;16(2):86-91. doi: 10.1016/j.cllc.2014.09.011. Epub 2014 Oct 13. Clin Lung Cancer. 2015. PMID: 25458559 Review.
The accelerated approval of potent ALK inhibitors, such as crizotinib and more recently ceritinib (LDK378), based on the well designed phase I/II trials has been a landmark success in clinical cancer research and contributes a new era of oncogenic targeted therapy characte …
The accelerated approval of potent ALK inhibitors, such as crizotinib and more recently ceritinib (LDK378), based on the well designe …
Ceritinib: a new tyrosine kinase inhibitor for non-small-cell lung cancer.
Cooper MR, Chim H, Chan H, Durand C. Cooper MR, et al. Ann Pharmacother. 2015 Jan;49(1):107-12. doi: 10.1177/1060028014553619. Epub 2014 Sep 25. Ann Pharmacother. 2015. PMID: 25258420 Review.
OBJECTIVE: To review ceritinib for the treatment of anaplastic lymphoma kinase (ALK)-positive metastatic non-small-cell lung cancer (NSCLC). ...Long-term data are needed to further define the role of ceritinib in the treatment of NSCLC....
OBJECTIVE: To review ceritinib for the treatment of anaplastic lymphoma kinase (ALK)-positive metastatic non-small-cell lung cancer ( …
Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy.
Santarpia M, Daffinà MG, D'Aveni A, Marabello G, Liguori A, Giovannetti E, Karachaliou N, Gonzalez Cao M, Rosell R, Altavilla G. Santarpia M, et al. Drug Des Devel Ther. 2017 Jul 5;11:2047-2063. doi: 10.2147/DDDT.S113500. eCollection 2017. Drug Des Devel Ther. 2017. PMID: 28740365 Free PMC article. Review.
In Phase I and II studies, ceritinib demonstrated pronounced activity in both crizotinib-naive and crizotinib-refractory patients, with responses observed regardless of the presence of ALK resistance mutations. ...We provide an extensive overview of ceritinib from t …
In Phase I and II studies, ceritinib demonstrated pronounced activity in both crizotinib-naive and crizotinib-refractory patients, wi …
142 results